Terms: = Brain cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Prognosis
282 results:
1. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
[No Abstract] [Full Text] [Related]
2. LINC00606 promotes glioblastoma progression through sponge miR-486-3p and interaction with ATP11B.
Dong N; Qi W; Wu L; Li J; Zhang X; Wu H; Zhang W; Jiang J; Zhang S; Fu W; Liu Q; Qi G; Wang L; Lu Y; Luo J; Kong Y; Liu Y; Zhao RC; Wang J
J Exp Clin Cancer Res; 2024 May; 43(1):139. PubMed ID: 38725030
[TBL] [Abstract] [Full Text] [Related]
3. Multi-Omics Pan-cancer Analysis of Procollagen N-Propeptidase Gene Family of ADAMTS as Novel Biomarkers to Associate with prognosis, Tumor Immune Microenvironment, Signaling Pathways, and Drug Sensitivities.
Chen Y; Xiao C; Fan Q; Zhang Y; Huang Q; Ou Y
Front Biosci (Landmark Ed); 2024 Apr; 29(4):151. PubMed ID: 38682182
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA NDUFA6-DT: A Comprehensive Analysis of a Potential LncRNA Biomarker and Its Regulatory Mechanisms in Gliomas.
Huang R; Kong Y; Luo Z; Li Q
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674418
[TBL] [Abstract] [Full Text] [Related]
5. Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype.
Dundar B; Alsawas M; Masaadeh A; Conway K; Snow AN; Sompallae RR; Bossler AD; Ma D; Lopes Abath Neto O
Pathol Res Pract; 2024 May; 257():155272. PubMed ID: 38631135
[TBL] [Abstract] [Full Text] [Related]
6. IQGAP3 promotes the progression of glioma as an immune and prognostic marker.
Gao X; Ge J; Gao X; Mei NA; Su Y; Shan S; Qian W; Guan J; Zhang Z; Wang L
Oncol Res; 2024; 32(4):659-678. PubMed ID: 38560572
[No Abstract] [Full Text] [Related]
7. Effect of gold-conjugated resveratrol nanoparticles on glioma cells and its underlying mechanism.
Liu X; Guo Z; Li J; Wu D; Liu Z; Guan C; Guan Y; Lu X
Biomed Mater Eng; 2024; 35(3):279-292. PubMed ID: 38461500
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
9. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
10. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract] [Full Text] [Related]
11. Advances in genetic abnormalities, epigenetic reprogramming, and immune landscape of intracranial germ cell tumors.
Zhang Y; Zhong C; Ke X; Liu J; Ye Z; Lu L; Deng K; Zhu H; Yao Y
Acta Neuropathol Commun; 2023 Nov; 11(1):188. PubMed ID: 38012690
[TBL] [Abstract] [Full Text] [Related]
12. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and pi3k-AKT pathway.
Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
[TBL] [Abstract] [Full Text] [Related]
13. Protein Disulfide Isomerase A2 Is Correlated with Immune Infiltrates and Is a Novel Prognostic Biomarker in Glioma Patients.
Ma ZG; Liu YX; Zou N; Huang Z; Wang M; Li T; Zhou J; Chen LG
Curr Med Sci; 2023 Dec; 43(6):1107-1115. PubMed ID: 37978154
[TBL] [Abstract] [Full Text] [Related]
14. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract] [Full Text] [Related]
15. Multiomics and bioinformatics identify differentially expressed effectors in the brain of
Yuan H; Jiang T; Zhang WD; Yang Z; Luo S; Wang X; Zhu X; Qi S; Mahmmod YS; Zhang XX; Yuan ZG
Front Cell Infect Microbiol; 2023; 13():1267629. PubMed ID: 37818043
[TBL] [Abstract] [Full Text] [Related]
16. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract] [Full Text] [Related]
17. PHLPP2: A Prognostic Biomarker in Adenocarcinoma of the Rectum.
Xie K
Turk J Gastroenterol; 2023 Oct; 34(10):1099-1106. PubMed ID: 37737218
[TBL] [Abstract] [Full Text] [Related]
18. Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration.
Sun JM; Fan HY; Zhu Y; Pan TT; Wu YP; Zhang DY; Hou XY
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37734869
[TBL] [Abstract] [Full Text] [Related]
19. Toward Precision Oncology in Glioblastoma with a Personalized cancer Genome Reporting Tool and Genetic Changes Identified by Whole Exome Sequencing.
Erdogan O; Özkaya ŞÇ; Erzik C; Bilguvar K; Arga KY; Bayraklı F
OMICS; 2023 Sep; 27(9):426-433. PubMed ID: 37669106
[TBL] [Abstract] [Full Text] [Related]
20. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.
Chen W; Guo S; Wang Y; Shi Y; Guo X; Liu D; Li Y; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Wang Y; Ma W
Cancer Med; 2023 Sep; 12(18):18666-18678. PubMed ID: 37667984
[TBL] [Abstract] [Full Text] [Related]
[Next]
